| Recruiting | A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytope Myelofibrosis, Moderate Thrombocytopenia, Mild Thrombocytopenia | Phase 2 | 2024-04-22 |
| Recruiting | Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recur Endometrial Cancer | Phase 3 | 2023-04-18 |
| Terminated | A Study to Evaluate the Safety and Efficacy of Selinexor With or Without Pembrolizumab Versus Standard of Care Metastatic Colorectal Cancer | Phase 2 | 2021-06-29 |
| Terminated | Safety and Efficacy of Selinexor in Combination With Pembrolizumab in Recurrent Advanced Melanoma Locally Advanced Unresectable or Metastatic Melanoma | Phase 2 | 2021-05-12 |
| Active Not Recruiting | A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants With Previously Treated M Myelofibrosis | Phase 2 | 2021-03-17 |
| Active Not Recruiting | Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis Myelofibrosis | Phase 3 | 2021-03-11 |
| Withdrawn | Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Relapsed or Refractory Diffuse Large B-Cell Lymphoma | Phase 1 / Phase 2 | 2020-11-18 |
| Recruiting | A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Rel Relapsed/Refractory Diffuse Large B-cell Lymphoma | Phase 2 / Phase 3 | 2020-09-03 |
| Recruiting | A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Multiple Myeloma, Refractory | Phase 2 | 2020-07-01 |
| Terminated | A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastom Glioblastoma Multiforme | Phase 1 / Phase 2 | 2020-06-08 |
| Withdrawn | Evaluation of Activity and Safety of Two Regimens of Low Dose Oral Selinexor in Participants With Moderate or Coronavirus Infection | Phase 2 | 2020-04-30 |
| Completed | Evaluation of Activity and Safety of Oral Selinexor in Participants With Severe COVID-19 Infection Coronavirus Infection | Phase 2 | 2020-04-17 |
| Completed | Relative Bioavailability/Bioequivalence of Different Formulations of Selinexor, the Impact of Hepatic Impairme Non-Small Cell Lung Carcinoma (NSCLC), Colorectal Cancer (CRC), Other Solid Tumors | Phase 1 / Phase 2 | 2020-01-14 |
| Completed | Maintenance With Selinexor/Placebo After Combination Chemotherapy in Participants With Endometrial Cancer [SIE Endometrial Cancer | Phase 3 | 2018-01-05 |
| Completed | Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple Myeloma Multiple Myeloma | Phase 3 | 2017-05-24 |
| Terminated | PAK4 and NAMPT in Patients With Solid Malignancies or NHL (PANAMA) Solid Tumors, NHL | Phase 1 | 2016-06-08 |
| Completed | Selinexor in Advanced Liposarcoma Dedifferentiated Liposarcoma | Phase 2 / Phase 3 | 2016-01-04 |
| Completed | Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Ind Relapsed/Refractory Multiple Myeloma (RRMM), Metastatic Colorectal Cancer (mCRC), Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Phase 1 / Phase 2 | 2016-01-01 |
| Withdrawn | Selinexor, Carfilzomib, and Dexamethasone Versus Placebo, Carfilzomib, and Dexamethasone in Multiple Myeloma Multiple Myeloma | Phase 2 | 2015-12-01 |
| Withdrawn | Efficacy & Safety Study of KPT-330 in Erythropoietin-Refractory Lower-Risk Myelodysplastic Syndrome Patients Myelodysplastic Syndrome | Phase 2 | 2015-11-01 |
| Recruiting | Selinexor and Backbone Treatments of Multiple Myeloma Patients Multiple Myeloma | Phase 1 / Phase 2 | 2015-10-01 |
| Withdrawn | Study of Selinexor (KPT- 330), Lenalidomide, & Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients Multiple Myeloma | Phase 1 / Phase 2 | 2015-07-01 |
| Terminated | Trial of Safety and Tolerability of Oral Verdinexor (KPT-335) in Healthy Adults Healthy | Phase 1 | 2015-05-26 |
| Completed | Selinexor Treatment of Refractory Myeloma Multiple Myeloma | Phase 2 | 2015-05-26 |
| Terminated | Efficacy and Safety Study of Selinexor in Relapsed or Refractory Peripheral T-cell Lymphoma or Cutaneous T-cel Peripheral T-cell Lymphoma (PTCL), Cutaneous T-cell Lymphoma (CTCL) | Phase 2 | 2015-02-01 |
| Withdrawn | Study of Safety, Tolerability, and Pharmacokinetics of Topical Selinexor (KPT-330) Diabetic Foot Ulcer (DFU) P Diabetic Foot Ulcers | Phase 1 / Phase 2 | 2015-01-01 |
| Terminated | Selinexor in Initial or Refractory and/or Relapsed Richter's Transformation Richter's Transformation | Phase 2 | 2014-11-14 |
| Recruiting | Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Diffuse Large B-cell Lymphoma | Phase 2 | 2014-11-01 |
| Terminated | Selinexor Treatment of Advanced Relapsed/Refractory Squamous Cell Carcinomas Squamous Cell Carcinoma | Phase 2 | 2014-09-22 |
| Terminated | SHIP (Selinexor in Hormone Insensitive Prostate Cancer) Prostate Cancer | Phase 2 | 2014-05-01 |
| Completed | Study of KPT-330 (Selinexor) in Female Patients With Advanced Gynaecologic Malignancies Ovarian Carcinoma, Endometrial Carcinoma, Cervical Carcinoma | Phase 2 | 2014-04-09 |
| Terminated | Study Evaluating the Efficacy and Safety of Selinexor (KPT-330) in Participants With Recurrent Gliomas Glioblastoma, Glioma | Phase 2 | 2014-03-03 |
| Completed | Selinexor (KPT-330) in Older Patients With Relapsed AML Acute Myeloid Leukemia (AML) | Phase 2 | 2014-03-01 |
| Completed | A Phase I Trial to Assess the Effects of Food and Formulation on PK of KPT-330 in Patients With Sarcoma Sarcoma | Phase 1 | 2013-07-30 |
| Completed | Safety Study of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients With Advanced Hematologic Hematological Malignancies | Phase 1 | 2012-07-23 |
| Completed | Safety Study of KPT-330 (Selinexor) in Patients With Advanced or Metastatic Solid Tumor Cancer Solid Tumor | Phase 1 | 2012-06-18 |
| Available | Karyopharm Expanded Access Program for Selinexor Multiple Myeloma, Diffuse Large B-Cell Lymphoma (DLBCL), Sarcoma | — | — |